TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01461720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard medical care
Description: Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem cells
Description: Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.
Study: NCT01702194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211 IV [C14]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211 PO [C14]
Study: NCT01021475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visceral Manipulation
Description: Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks and 4 VM visits with weekly frequency with first VM visit at day 1 of drug therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPIs and/or Domperidone
Description: Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks
Study: NCT01045083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: Oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: Oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral single dose
Study: NCT00990665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-D and LV lead (Quartet™ lead and Promote Q® device system)
Description: Promote Q CRT-D and Quartet LV lead
Study: NCT00526903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elimination Diet
Description: Daily diet change for 8 days.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Elimination Diet
Description: Daily diet change for 8 days.
Study: NCT03376347

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FlotracIQ with HPI algorithm
Description: FlotracIQ with hypotension probability indicator (HPI) algorithm connected to arterial line. The treating anesthetist is provided with guidance by means of a flowchart suggesting when to treat and what. Timing of treatment and choice of treatment is then left to the discretion of the attending physician.
Study: NCT00756392

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3T MR Spectroscopy
Description: A Magnetic Resonance Spectroscopy (MRS)study of a patient's prostate will be conducted with the 3 Tesla Philips Intera Nuclear Magnetic Resonance (NMR) scanner before and after filling the rectum with barium. Scan duration from Preparation to Completion will be approximately 30 minutes. The spectra will be acquired without and with the presence of Barium solution to compare to see if the latter is advantageous.
Study: NCT00813670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-001
Description: Single oral dose, or 6 days of repeated oral doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-001
Description: Single oral dose, or 6 days of repeated oral doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-001
Description: Single oral dose, or 6 days of repeated oral doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-001
Description: Single oral dose, or 6 days of repeated oral doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-001
Description: Single oral dose, or 6 days of repeated oral doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-001
Description: Single oral dose, or 6 days of repeated oral doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-001
Description: Single oral dose, or 6 days of repeated oral doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-001
Description: Single oral dose, or 6 days of repeated oral doses.
Study: NCT04505384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left bundle branch pacing
Description: left bundle branch pacing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biventricular pacing
Description: biventricular pacing
Study: NCT00256321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 70mg/m2 IV on Days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m2 PO BID from Days 1 through 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 400mg PO BID from Days 1 through 21.
Study: NCT03149120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib given at a dose of 800 mg by mouth daily.
Study: NCT03269084

Intervention type: OTHER
Intervention: No intervention. DIPP is an observational study.
Study: NCT01600274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest-Ethinyl Estradiol (test product)
Description: One tablet of Test

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest-Ethinyl Estradiol (reference product)
Description: One tablet of Reference
Study: NCT02407054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT01482962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib enteric coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pralatrexate
Description: Pralatrexate IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romidepsin
Description: Romidepsin IV infusion
Study: NCT01942317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balneotherapy
Study: NCT01498224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReSure Sealant
Description: Comparison of ReSure Sealant to suture(s)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sutures
Study: NCT01718834

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: prophylactic peptide vaccine
Description: synthetic peptide vaccine derived from HCV E1 and HCV E2 will be used for immunization of healthy volunteers

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic peptide vaccine
Description: therapeutic peptide vaccine will immunize to HCV chronic HCV patients non responders to INF
Study: NCT02455609

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal drug administration
Description: pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal drug administration
Description: pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal drug administration
Description: pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study: NCT01907061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: drug will be administered via IV,NG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: drug will be administered via IV,NG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: drug will be administered via IV,NG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo or NAC will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo or NAC will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo or NAC will be given
Study: NCT00373009

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Traditional Army training
Description: As usual training for Soldiers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Core stabilization exercise only
Description: Core stabilization exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial education class only
Description: Psychosocial education class

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core stabilization and psychosocial education
Description: Includes both core stabilization training and psychosocial education class
Study: NCT02326298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use
Study: NCT01797081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (24 U)
Description: 24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: botulinum toxin Type A (24 U)
Description: 24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (12 U)
Description: 12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: botulinum toxin Type A (12 U)
Description: 12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline
Description: Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline
Description: Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.
Study: NCT00737893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Description: Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.
Study: NCT04253782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Team Intervention
Description: The Team will meet with participants (remotely/electronically and/or by phone) and will ask that they select one of three options that may help with opioid addiction:~1. treatment with buprenorphine/naloxone (BUP),~2. inpatient, 12-step, or methadone regimens, or~3. education only (materials provided by the CT Community for Addiction Recovery (CCAR)).~Throughout the study, participants may switch to any other option.
Study: NCT05028413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participants Shown their Breath Alcohol Content Measurement
Description: Each time a Breath Alcohol Content (BrAC) Measurement is taken by the research team, the participant is shown the measurement before completing the paper visual analog scale scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
Study: NCT03634436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous
Study: NCT01981343

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A-F Betafood

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02829827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiprodil
Description: Radiprodil at individualized doses.
Study: NCT00270231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule.
Study: NCT01203826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asfotase Alfa
Study: NCT03042871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg intravitreal ranibizumab
Description: Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg intravitreal ranibizumab
Description: Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days
Study: NCT01534208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
Study: NCT01928225

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus vaccine
Description: The participants receive the qHPV vaccine at entry, week 4 and week 26

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Human Papillomavirus vaccine
Description: The participants receive the qHPV vaccine at entry, week 4 and week 26
Study: NCT04522713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation, evidence-based sleep strategies including sleep restriction, exposure-based strategies, promotion of physical activity and recuperating activities, psychoeducational material
Description: Primarily standard cognitive-behavioral strategies to reduce common psychiatric symptoms
Study: NCT00701337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oestradiol
Description: oestradiol 2 mg oral route 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oestradiol
Description: oestradio transdermal patch 60ug by 24 hours 30 days
Study: NCT03492619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Intervention
Description: an intervention focused on alleviating discouragement, food insecurity, and excess weight in women and targeted at the individual, family, and community levels

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Intensive Intervention
Description: Group sessions for healthy lifestyle
Study: NCT01768754

Intervention type: BEHAVIORAL
Intervention: Usual and Fast Walking Speeds
Description: Stable patients with chronic obstructive pulmonary disease will demonstrate their usual and fast walking speeds over a 30 m course, with speed calculated over the middle 10 m using optical sensors. The test will be repeated after a 5 minute rest; this procedure will then be repeated on two subsequent days, at the same time of day, within one week.
Study: NCT00594906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
Study: NCT02096614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBI-1201
Description: TBI-1201(5\*10\^8 or 5\*10\^9) is administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBI-1201
Description: TBI-1201(5\*10\^8 or 5\*10\^9) is administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBI-1201
Description: TBI-1201(5\*10\^8 or 5\*10\^9) is administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBI-1201
Description: TBI-1201(5\*10\^8 or 5\*10\^9) is administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201
Study: NCT01562483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to the Namisol arm.
Study: NCT00745121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™
Description: ASTRA TECH Implant System, OsseoSpeed™ implants Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™
Description: ASTRA TECH Implant System, OsseoSpeed™ implants Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm
Study: NCT01018797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INTRASTROMAL CORNEAL RING SEGMENT
Description: Corneal tunnels were created by means of mechanical dissection in all eyes. Intrastromal corneal ring segments implantation was indicated because of the existence of reduced best spectacle-corrected visual acuity (BSCVA) or contact lens intolerance.
Study: NCT04064723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Randomization between prosthetic components
Description: Patients are randomized between two types of stem components and two types of cup components in total hip arthroplasty. Thus randomized between 4 different groups.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Randomization between prosthetic components
Description: Patients are randomized between two types of stem components and two types of cup components in total hip arthroplasty. Thus randomized between 4 different groups.
Study: NCT01880697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIVc
Description: Trivalent Influenza Virus Vaccine (surface antigen, inactivated, cell-based)